{"id":"msb0010718c","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:15:50.437689","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MSB0010718C is an individualized neoantigen-based immunotherapy that combines personalized tumor mutation profiling with immunogenic peptide sequences to stimulate CD8+ T-cell responses against patient-specific cancer mutations. The vaccine is typically administered in combination with checkpoint inhibitors to enhance anti-tumor immunity. This approach aims to generate durable, personalized immune responses targeting the unique mutational landscape of each patient's tumor.","oneSentence":"MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:21.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (in combination with checkpoint inhibitors)"},{"name":"Non-small cell lung cancer (in combination with checkpoint inhibitors)"}]},"_fixedFields":["sideEffects","modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT06225596","phase":"PHASE2, PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":"Metastatic Urothelial Cancer","enrollment":956},{"nctId":"NCT04261855","phase":"PHASE1, PHASE2","title":"Targeted Therapy and Avelumab in Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-08","conditions":"Metastatic Merkel Cell Carcinoma","enrollment":19},{"nctId":"NCT03076554","phase":"PHASE2","title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-19","conditions":"Thymoma, Thymic Carcinoma","enrollment":56},{"nctId":"NCT04071236","phase":"PHASE1, PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":90},{"nctId":"NCT05092958","phase":"PHASE3","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-03","conditions":"Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma","enrollment":654},{"nctId":"NCT05947500","phase":"PHASE2","title":"Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-21","conditions":"Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma","enrollment":50},{"nctId":"NCT04068194","phase":"PHASE1, PHASE2","title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-07","conditions":"Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma","enrollment":103},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT06228066","phase":"PHASE2","title":"Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-13","conditions":"Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract","enrollment":45},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT04004442","phase":"PHASE1","title":"Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oklahoma","startDate":"2020-02-17","conditions":"Urothelial Carcinoma","enrollment":19},{"nctId":"NCT07460245","phase":"PHASE2","title":"Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-06","conditions":"Urothelial Carcinoma","enrollment":144},{"nctId":"NCT03719768","phase":"PHASE1","title":"Avelumab With Radiotherapy in Patients With Leptomeningeal Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-10","conditions":"Leptomeningeal Metastases, Leptomeningeal Disease","enrollment":16},{"nctId":"NCT06412848","phase":"","title":"JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-05-09","conditions":"Urothelial Carcinoma","enrollment":360},{"nctId":"NCT03006848","phase":"PHASE2","title":"A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-02-16","conditions":"Osteosarcoma","enrollment":19},{"nctId":"NCT03252938","phase":"PHASE1","title":"Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2017-08-15","conditions":"Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma","enrollment":83},{"nctId":"NCT05396833","phase":"PHASE1","title":"Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-06-07","conditions":"Metastatic or Locally Advanced Unresectable Solid Tumors","enrollment":120},{"nctId":"NCT04848519","phase":"PHASE2","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":6},{"nctId":"NCT05267626","phase":"PHASE1, PHASE2","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Aulos Bioscience, Inc.","startDate":"2022-04-04","conditions":"Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma","enrollment":159},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT06939036","phase":"PHASE1, PHASE2","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","status":"TERMINATED","sponsor":"Ariceum Therapeutics GmbH","startDate":"2025-07-01","conditions":"Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma","enrollment":2},{"nctId":"NCT03944941","phase":"PHASE2","title":"Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-06-17","conditions":"Skin Squamous Cell Carcinoma, Metastatic Skin Cancer","enrollment":60},{"nctId":"NCT03260023","phase":"PHASE1, PHASE2","title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Transgene","startDate":"2017-09-01","conditions":"HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT05139706","phase":"","title":"Montreal Immune-Related Adverse Events (MIRAE) Study","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-01-21","conditions":"Cancer, Immune System Disorder, Inflammatory Reaction","enrollment":1000},{"nctId":"NCT05327530","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-17","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":256},{"nctId":"NCT05081180","phase":"PHASE1","title":"Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2021-12-03","conditions":"Central Nervous System Tumors","enrollment":17},{"nctId":"NCT04701918","phase":"PHASE2","title":"Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-06-04","conditions":"Metastatic Urothelial Carcinoma, Bladder Cancer","enrollment":9},{"nctId":"NCT04360941","phase":"PHASE1","title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-08-11","conditions":"Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer","enrollment":45},{"nctId":"NCT06302426","phase":"PHASE1","title":"Trial of INI-4001 in Patients With Advanced Solid Tumours","status":"RECRUITING","sponsor":"Inimmune Corporation","startDate":"2024-07-01","conditions":"Advanced Solid Tumor","enrollment":50},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":240},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT07110038","phase":"PHASE2","title":"DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-16","conditions":"Penile Squamous Cell Carcinoma (PSCC)","enrollment":25},{"nctId":"NCT04260802","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","status":"TERMINATED","sponsor":"Ocellaris Pharma, Inc.","startDate":"2020-09-24","conditions":"Cancer, Neoplasms, Metastatic Cancer","enrollment":73},{"nctId":"NCT03744793","phase":"PHASE2","title":"Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-11","conditions":"Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation","enrollment":18},{"nctId":"NCT07207928","phase":"","title":"Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2024-09-16","conditions":"Urothelial Cancer","enrollment":35},{"nctId":"NCT06518564","phase":"PHASE2","title":"Avelumab and M1774 in ARID1A-mutated Endometrial Cancer","status":"RECRUITING","sponsor":"Panagiotis Konstantinopoulos, MD, PhD","startDate":"2024-11-14","conditions":"Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma","enrollment":25},{"nctId":"NCT03135769","phase":"PHASE2","title":"Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-02-21","conditions":"Gestational Trophoblastic Neoplasias (GTN)","enrollment":24},{"nctId":"NCT03391479","phase":"PHASE2","title":"A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-08-15","conditions":"Penile Cancer, Advanced Cancer, Metastatic Cancer","enrollment":25},{"nctId":"NCT05419362","phase":"PHASE2","title":"GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer","status":"COMPLETED","sponsor":"Genome & Company","startDate":"2022-04-07","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":42},{"nctId":"NCT02926196","phase":"PHASE3","title":"Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2016-06-17","conditions":"Triple Negative Breast Neoplasms","enrollment":474},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT04188119","phase":"PHASE2","title":"A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT03815643","phase":"PHASE3","title":"Avelumab Program Rollover Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-03-22","conditions":"Solid Tumors","enrollment":205},{"nctId":"NCT03575013","phase":"PHASE1","title":"A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2018-10-29","conditions":"Urothelial Carcinoma","enrollment":21},{"nctId":"NCT05366725","phase":"","title":"A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-06-29","conditions":"Urothelial Cancer","enrollment":106},{"nctId":"NCT04941768","phase":"","title":"An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-08-09","conditions":"Carcinoma, Renal Cell","enrollment":105},{"nctId":"NCT05287464","phase":"","title":"International Multicentric Study ARON-1","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2022-03-10","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":1220},{"nctId":"NCT04266912","phase":"PHASE1, PHASE2","title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-17","conditions":"Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":23},{"nctId":"NCT07225374","phase":"PHASE2","title":"Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-09-16","conditions":"Upper Tract Urothelial Carcinoma","enrollment":48},{"nctId":"NCT03747419","phase":"PHASE2","title":"Avelumab and Radiation in Muscle-Invasive Bladder Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-12-13","conditions":"Bladder Cancer, Muscle Invasive Bladder Cancer","enrollment":14},{"nctId":"NCT03217747","phase":"PHASE1, PHASE2","title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-02","conditions":"Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm","enrollment":173},{"nctId":"NCT06557278","phase":"PHASE2","title":"Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Mirror Biologics, Inc.","startDate":"2026-11","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT04954599","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2023-05-30","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":126},{"nctId":"NCT03147287","phase":"PHASE2","title":"Palbociclib After CDK and Endocrine Therapy (PACE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-09-05","conditions":"Metastatic Breast Cancer","enrollment":220},{"nctId":"NCT04678362","phase":"PHASE2","title":"TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma","status":"RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2021-06-01","conditions":"Urothelial Carcinoma","enrollment":50},{"nctId":"NCT03271372","phase":"PHASE3","title":"Adjuvant Avelumab in Merkel Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2017-12-19","conditions":"Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8","enrollment":101},{"nctId":"NCT04258956","phase":"PHASE2","title":"A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy","status":"COMPLETED","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2019-04-30","conditions":"Gastrointestinal Stromal Tumors","enrollment":58},{"nctId":"NCT04510597","phase":"PHASE3","title":"Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2021-03-08","conditions":"Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":364},{"nctId":"NCT04887831","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-06-04","conditions":"Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult","enrollment":92},{"nctId":"NCT04242238","phase":"PHASE1","title":"Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-01-22","conditions":"Sarcoma, Advanced Sarcoma, High Grade Sarcoma","enrollment":32},{"nctId":"NCT04792073","phase":"PHASE2","title":"Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-03-08","conditions":"Merkel Cell Carcinoma","enrollment":18},{"nctId":"NCT05222932","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2023-03-08","conditions":"Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT02684006","phase":"PHASE3","title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03-23","conditions":"Renal Cell Cancer","enrollment":886},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT02912572","phase":"PHASE2","title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-14","conditions":"Metastatic Endometrial Cancer","enrollment":106},{"nctId":"NCT03414658","phase":"PHASE2","title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2018-06-21","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT03737721","phase":"PHASE2","title":"The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2019-04-12","conditions":"Squamous Cell Carcinoma of the Skin","enrollment":8},{"nctId":"NCT03357757","phase":"PHASE2","title":"Avelumab With Valproic Acid in Virus-associated Cancer","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2018-02-07","conditions":"Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix","enrollment":39},{"nctId":"NCT05059522","phase":"PHASE3","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-09-29","conditions":"Advanced Malignancies, NSCLC, Ovarian Cancer","enrollment":68},{"nctId":"NCT05687721","phase":"PHASE1, PHASE2","title":"Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2025-06-02","conditions":"Advanced Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03826589","phase":"NA","title":"Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Cervical Cancer","enrollment":23},{"nctId":"NCT03047473","phase":"PHASE2","title":"Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Clinique Neuro-Outaouais","startDate":"2017-05-19","conditions":"Glioblastoma Multiforme of Brain","enrollment":38},{"nctId":"NCT03964532","phase":"PHASE1, PHASE2","title":"TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2019-04-17","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT05102721","phase":"PHASE1, PHASE2","title":"Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaccinex Inc.","startDate":"2022-12-10","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":48},{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03971409","phase":"PHASE2","title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2019-07-08","conditions":"Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":150},{"nctId":"NCT05217069","phase":"PHASE2","title":"FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-09-27","conditions":"Treatment Related Cancer","enrollment":57},{"nctId":"NCT03724890","phase":"PHASE1","title":"Study of Avelumab-M3814 Combinations","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2018-11-27","conditions":"Oncology, Solid Tumors","enrollment":57},{"nctId":"NCT04291885","phase":"PHASE2","title":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-26","conditions":"Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II","enrollment":122},{"nctId":"NCT03498378","phase":"PHASE1","title":"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kathryn Gold","startDate":"2018-06-06","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT05431777","phase":"","title":"A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-07-19","conditions":"Urothelial Carcinoma","enrollment":79},{"nctId":"NCT03868046","phase":"","title":"Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)","status":"COMPLETED","sponsor":"Hospital Universitario Araba","startDate":"2019-08-25","conditions":"Cancer, Metastatic Cancer, Solid Organ Cancer","enrollment":242},{"nctId":"NCT05650164","phase":"","title":"Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2023-01-25","conditions":"Renal Cell Carcinoma","enrollment":171},{"nctId":"NCT03440567","phase":"PHASE1","title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":16},{"nctId":"NCT06892860","phase":"PHASE2","title":"Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-12-16","conditions":"Urinary Bladder Neoplasms","enrollment":320},{"nctId":"NCT06505746","phase":"","title":"A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2024-08-29","conditions":"Metastatic Urothelial Cancer","enrollment":287},{"nctId":"NCT04328844","phase":"PHASE1","title":"A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOnctura","startDate":"2020-02-25","conditions":"Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC","enrollment":210},{"nctId":"NCT03893903","phase":"PHASE1","title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","status":"COMPLETED","sponsor":"German Cancer Research Center","startDate":"2018-10-19","conditions":"Malignant Glioma","enrollment":69},{"nctId":"NCT06869473","phase":"PHASE2","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-02-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":67},{"nctId":"NCT04841148","phase":"PHASE2","title":"Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-06-01","conditions":"Breast Cancer","enrollment":96},{"nctId":"NCT03747484","phase":"PHASE1, PHASE2","title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-03","conditions":"Other Skin","enrollment":7},{"nctId":"NCT03674424","phase":"PHASE2","title":"Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2018-06-01","conditions":"Non-metastatic Muscle Invasive Bladder Cancer","enrollment":137},{"nctId":"NCT04322643","phase":"PHASE2","title":"Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-03-23","conditions":"Urothelial Carcinoma","enrollment":4},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avelumab"],"phase":"phase_3","status":"active","brandName":"MSB0010718C","genericName":"MSB0010718C","companyName":"Istituto Oncologico Veneto IRCCS","companyId":"istituto-oncologico-veneto-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}